EU/3/19/2170: Orphan designation for the treatment of beta-thalassaemia intermedia and major

2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridine-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride

Table of contents

Overview

On 28 June 2019, orphan designation EU/3/19/2170 was granted by the European Commission to Vifor France S.A., France, for 2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride (also known as VIT-2763) for the treatment of beta-thalassaemia intermedia and major.

Key facts

Active substance
2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridine-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride
Intended use
Treatment of beta-thalassaemia intermedia and major
Orphan designation status
Positive
EU designation number
EU/3/19/2170
Date of designation
28/06/2019
Sponsor

Vifor France S.A.
Tour Franklin La Defense 8
100-101 Terrasse Boieldieu
Puteaux
92042 Paris La Defense Cedex
France 
Tel. +33 1410 65890; +41 5885 18000 (Switzerland)
E-mail: info@viforpharma.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating